United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$397.49 USD
+14.72 (3.85%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$397.49 USD
+14.72 (3.85%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Zacks News
United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 3.40% and 4.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for United Therapeutics (UTHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
by Zacks Equity Research
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
by Zacks Equity Research
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.
Is First Trust Mid Cap Value AlphaDEX ETF (FNK) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNK
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
UTHR or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
by Zacks Equity Research
Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.
3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR)
by Zacks Equity Research
United Therapeutics (UTHR) could produce exceptional returns because of its solid growth attributes.